Dual targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy.

Dual targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy.

  • Post by:
  • May 16, 2019
  • Comments off
Categories:

Participating Institutions

University of Queensland
University of Sydney
Queensland University of Technology
Australian National University
Monash University
Edith Cowan University

CSIRO

 

 

International Partners

Boston Children’s Hospital
University of Washington
University of Tokyo
University of Oxford
Massachusetts Institute of Technology
Howard Hughes Medical Institute

University of Southampton

 

Our YouTube Channel

YouTube

Publications Statistics

22 leading Scientists

CIPPS brings together the expertise of 22 world-leading peptide and protein scientist.

1800 Publications

Cumulatively, CIPPS researchers have published over 1800 publications, books and book chapters in the past 10 years

310,000 Citations

CIPPS researchers have been cited over 310,000 times